[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356377-105":59,"doc-detail-356377-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-efficacy-of-immune-checkpoint-inhibitors-in-metastatic-castration-resistant-prostate-cancer-a-meta-analysis-and-reconstructed-individual-patient-data-analysis","The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer - A meta-analysis and reconstructed individual patient data analysis","","Some immune checkpoint inhibitors (ICI) have been used for men with metastatic castration-resistant prostate cancer (mCRPC), yet inconsistent results in unselected populations raise concerns. Primary outcomes were overall survival (OS) and radiographic progression-free survival (PFS), with objective response rate (ORR) as a secondary outcome. Individual patient data (IPD) were reconstructed from reported survival curves; Kaplan–Meier methods assessed efficacy. Data from 1580 patients across 21 trials showed pooled 1- and 2-year OS of 63% and 39%, and pooled 6- and 12-month PFS of 41% and 17%. ICI plus other agents improved OS and PFS versus mono/dual ICI (all P\u003C.05).",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-efficacy-of-immune-checkpoint-inhibitors-in-metastatic-castration-resistant-prostate-cancer-a-meta-analysis-and-reconstructed-individual-patient-data-analysis/356377/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-efficacy-of-immune-checkpoint-inhibitors-in-metastatic-castration-resistant-prostate-cancer-a-meta-analysis-and-reconstructed-individual-patient-data-analysis/356377.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How were individual patient data (IPD) reconstructed and evaluated?","Question",{"text":113,"@type":114},"IPD were reconstructed from reported survival curves, and efficacy was assessed using Kaplan–Meier methods.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What were the primary and secondary efficacy outcomes?",{"text":118,"@type":114},"Primary outcomes were overall survival (OS) and radiographic progression-free survival (PFS). Objective response rate (ORR) was included as a secondary outcome.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the pooled survival results show for unselected mCRPC patients?",{"text":122,"@type":114},"The pooled 1-year and 2-year OS were 63% and 39%, while pooled 6-month and 12-month PFS were 41% and 17%.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356377,1790641115,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","HUMAN VACCINES & IMMUNOTHERAPEUTICS 2026, VOL. 22, NO. 1, 2626084 [https://doi.org/10.1080/21645515.2026.2626084](https://doi.org/10.1080/21645515.2026.2626084)  \nREVIEW  \nThe efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis  \nFuxun Zhanga,b*, Yang Xiongc*, Zhirong Luoa*, Qi Xuea, Lei Wanga, Qiang Fua, Wei Zhanga, Pati-Alam Alishab, Uzoamaka Adaobi Okolib,d, and Geng Zhang a  \naDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China; bDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; cDivision of Surgery & Interventional Science, University College London, London, UK; dBasic and Translational Cancer Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria, Nsukka, Nigeria  \nABSTRACT  \nSome immune checkpoint inhibitors (ICI) has been used for men with specific metastatic castration-resistant prostate cancer (mCRPC) . However, inconsistent results of ICI for unselected mCRPC population raise concerns. The primary outcomes were overall survival (OS) and radiographic progression-free survival (PFS), and the secondary outcomes included objective response rate (ORR) . Individual patient data (IPD) were reconstructed from reported survival curve, and Kaplan–Meier method was used to evaluate the efficacy. Data of 1580 patients from 21 clinical trials were analyzed without biomarker-selected indications. The pooled 1-y and 2-y OS were 63% and 39%, while pooled 6-month and 12-month PFS were 41% and 17% . ICI plus other agent showed more OSand PFS benefits comparing with mono or dual ICI therapy (All P \u003C .05) . Combination therapy with ICI showed encouraging but preliminary signs in mCRPC. Future large trials focusing on combination regimens of ICI are needed.  \nRegistration: PROSPERO (CRD420251087847) .  \nARTICLE HISTORY  \nReceived 15 October 2025 Revised 17 January 2026 Accepted 27 January 2026  \nKEYWORDS  \nProstate cancer; immune checkpoint inhibitor; immunotherapy; efficacy; safety; individual patient data  \nIntroduction  \nProstate cancer (PCa) is a leading cause of cancer-related mortality in men with around 400,000 deaths worldwide each year. 1,2 Combination of androgen deprivation therapy (ADT) plus androgen receptor pathway inhibitors (ARPIs) currently constitutes the standard of care for high-risk localized PCa, metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) .3,4 Among them, mCRPC as an end stage is almost inevitable and incurable.5 In recent years, several new treatments for mCRPC have been used to delay the disease progression, such as poly(ADPribose) polymerase inhibitors (PARPIs), novel ARPIs and radioligand therapy.6–10 However, mCRPC is still a lethal condition due to irreversible disease progression and drug resistance regardless of initial  \nresponse. 11, 12 Thus, clinical trials exploring the management of mCRPC are constantly increasing.  \nImmunotherapy is developing and transforming as an effective cancer treatment currently.13, 14 Immune checkpoint inhibitor (ICI), an important progression of immunotherapy that works by utilizing the host immune system to target tumor cells, has been applied in many malignancies including genitourinary and gastrointestinal cancers. 15–18 For patients with mCRPC refractory to standard of care, ICI treatment asa potentially effective approach has been tested in many clinical trials over the past decade.3, 19 In this regard, cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L1) inhibitors have been evaluated in mCRPC by many clinical trials. 11, 12 Specifically,  \nCONTACT Uzoamaka Adaobi Okoli  [u.okoli@ucl.ac.uk](u.okoli@ucl.ac.uk)  Division of Surgery & Interventional Science, University College Lo","cbCaimIZGeAQhrwR","https://ap.wps.com/l/cbCaimIZGeAQhrwR","pdf",5409636,"English","# Introduction\n# Methods\n# Results\n# Discussion\n# Conclusion","[{\"question\":\"How were individual patient data (IPD) reconstructed and evaluated?\",\"answer\":\"IPD were reconstructed from reported survival curves, and efficacy was assessed using Kaplan–Meier methods.\"},{\"question\":\"What were the primary and secondary efficacy outcomes?\",\"answer\":\"Primary outcomes were overall survival (OS) and radiographic progression-free survival (PFS). Objective response rate (ORR) was included as a secondary outcome.\"},{\"question\":\"What did the pooled survival results show for unselected mCRPC patients?\",\"answer\":\"The pooled 1-year and 2-year OS were 63% and 39%, while pooled 6-month and 12-month PFS were 41% and 17%.\"}]","The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer - A meta-analysis and reconstructed individual patient data analysis | PDF",1790125087,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe7c6c4c0e53d531d065a26530284242.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1cc9a0a6e2aeac78662a0f25a54e8180.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36e1574c0f925bbc97307d7458064d76.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a09dad2829bb0bc82b2a57284ad0658.webp",980,1306]